Structure of CT market

* Data from www.roszdravnadzor.ru

** Data from http://grls.rosminzdrav.ru

* The phases of CT are quoted as indicated in protocols

Data from www.roszdravnadzor.ru

The data of Russian clinical trial market dynamics is based on the official information of Roszdravnadzor about approved clinical trials in 2009. In our opinion the decrease in the general number of approved clinical trials in 2009 (4,4% for international multicentre clinical trials and 6,2% for general number of clinical trials) was a result of global crisis impact. The similar and even bigger decrease in the global number of clinical trials (according with the information from www.ClinicalTrials.gov) is typical of many countries (see the Table).

Comparison of intervention clinical trials number among different countries (for period 2008-2009)*

Ñountry	number of CT 2008	number of CT 2009	Percents, %		Country	number of CT 2008	number of CT 2009	Percents, %
China	307	363	+18,2		Switzerland	242	235	-2,9
Brazil	357	335	-6,2		France	867	819	-5,5
Taiwan	242	218	-10,1		Japan	310	286	-7,7
India	277	213	-23,1		United Kingdom	780	718	-7,9
Turkey	120	89	-25,8		Denmark	335	306	-8,7
Mexico	225	161	-28,4		Germany	1048	934	-10,9
Poland	361	253	-29,9		United States	7138	6196	-13,2
Hungary	211	139	-34,1		Israel	347	303	-12,7
Latvia	59	38	-35,6		Sweden	356	303	-14,9
Croatia	55	35	-36,4		Norway	207	171	-17,4
Czech Republic	242	150	-38,0		Canada	1136	938	-17,4
Slovakia	126	76	-39,7		Netherlands	489	388	-20,7
Romania	186	107	-42,5		Italy	627	488	-22,2
Portugal	91	51	-44,0		Finland	217	167	-23,0
Estonia	70	37	-47,1		Spain	596	447	-25,0
Ukraine	131	61	-53,4		Belgium	489	350	-28,4
Serbia	72	27	-62,5		Austria	314	208	-33,8

* Data from www.ClinicalTrials.gov 

* The phases of CT are quoted as indicated in protocols

* The phases of CT are quoted as indicated in protocols

* The phases of CT are quoted as indicated in protocols

* The phases of CT are quoted as indicated in protocols

* The phases of CT are quoted as indicated in protocols